Acurx Pharmaceuticals develops new antibiotics for hard to treat bacterial infections, based in Staten Island, New York. ACXP reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How ACXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ACXP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACXP is in one of them and how their past ACXP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACXP in an article yet. Here's the latest on the wider market.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company based in Staten Island, New York. It is developing a new class of small molecule antibiotics for bacterial infections that are hard to treat, including Clostridioides difficile infections, MRSA, and vancomycin resistant Enterococcus. Its lead candidate, ibezapolstat, works by blocking a bacterial enzyme called DNA pol IIIC and is in clinical trials. The company expects to partner with a larger drugmaker for later stage trials and commercialization, and its intended users are patients with these infections and the healthcare providers who treat them.
- Headquarters
- Staten Island, NY